Fig. 2.

Frequency of individual cases with specific SAEs and SAE-related deaths among BNT, ChA, and AD26 recipients divided according to age group. The frequency of individual cases with specific AEs divided according to age range (18–64 years and >64 years) was obtained by normalizing the number of individual cases with the doses apparently administered to each age range in Europe at week 23 (Table S7). We needed to evaluate the doses apparently administered to each age range in Europe. Hence, we considered the doses administered by the European countries providing data on the administration of each vaccine to these age ranges and established a method for evaluating the variance of the doses (see the Method section for details). The figure shows the frequency (mean ± SD) of individual cases with SAEs and SAE-related deaths consisting of coagulation disorders (venous thrombotic and hemorrhagic events, thrombocytopenia) and arterial, cardiac and nervous system events. Significance was calculated using the Welch and Brown-Forsythe one-way ANOVA; the difference between ChA and BNT, AD26 and BNT, and ChA and AD26 was assessed with Dunnett T3 multiple-comparison post-hoc analysis, and multiplicity-adjusted p-values are reported. ns (not significant) = p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.